Roivant.com Website Review

Roivant is focused on rapidly developing innovative medicines through a novel form of industrial organization in R&D. We believe that the key to unlocking innovation in drug discovery and commercialization is reducing the time and cost of the drug We do this by building Vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. Since 2014, Roivant has scaled its production of new Vants, with 14 fully built to date and additional Vants under construction. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. We also launch new healthcare technology companies to improve the process of developing and delivering all new medicines to patients.. FOUNDER AND CEO VIVEK RAMASWAMY PRESENTS AT ROIVANT PIPELINE DAY. Developing transformative therapies for patients with rare diseases. Looking beyond the current options for cardiometabolic disorders. We have a diverse pipeline of over 35 investigational drugs in 14 thera*eutic areas across our family of companies. Uterine fibroids are non-cancerous tumors that develop from the muscle and connective tissue of the uterus. Approximately 25% of women of reproductive age have uterine fibroids, and 1 in 4 experience symptoms requiring treatment. Although uterine fibroids are benign tumors, they may cause debilitating symptoms including heavy and prolonged menstrual bleeding, anemia, and pelvic pain. Current treatments include hormonal contraceptives, GnRH agonists, and surgical interventions including myomectomy and hysterectomy. Myovant is currently developing relugolix, an oral, once-daily, gonadotropin-releasing hormone (GnRH) receptor antagonist. By inhibiting GnRH receptors in the anterior pituitary gland, relugolix rapidly reduces the circulating gonadotropin luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to the suppression of estrogen in women and testosterone in men. Suppression of these